AstraZeneca’s Forxiga approved for extended use in EU for chronic heart failure

AstraZeneca - Factory

Editorial Fotonen/iStock via Getty Images

The European Commission (EC) approved AstraZeneca (NASDAQ: AZN) Forxiga for extended use for the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the spectrum of left ventricular ejection fraction (LVEF), including HF with mildly reduced and

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *